Completed PHASE4 INTERVENTIONAL 2-arm NCT05919173

Comparison Between Bupivacaine and Bupivacaine With Dexmedetomidine in Caudal Block for Post Operative Pain Control

UROLOGICAL SURGERIES IN CHILDREN: Comparison Between 0.25% Bupivacaine and 0.25% Bupivacaine withDexmedetomidine in the Caudal Block

Sponsor: Sindh Institute of Urology and Transplantation

Conditions Post Operative Pain

Interventions Bupivacaine Hydrochloride 0.25% Injection Solution Bupivacaine Hydrochloride 0.25% Injection plus Dexmedetomidine 1 microgram/kg body weight

Updated 4 times since 2023 Last updated: Jul 8, 2023 Started: Jul 10, 2021 Primary completion: Nov 15, 2021 Completion: Nov 20, 2021

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT05919173, this PHASE4 trial focuses on Post Operative Pain and remains completed. Sponsored by Sindh Institute of Urology and Transplantation, it has been updated 4 times since 2021, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

4 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE4
Jul 2024 — Sep 2024 [monthly]

Completed PHASE4
Aug 2023 — Jul 2024 [monthly]

Completed PHASE4
Jul 2023 — Aug 2023 [monthly]

Completed PHASE4

First recorded

Jul 2021

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Sindh Institute of Urology and Transplantation

Data source: Sindh Institute of Urology and Transplantation

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Karachi, Pakistan